SkinnyRx**
RightFit currently tracks 3 published programs from SkinnyRx covering weight management.
** State availability: Exact program-level state availability was not confirmed from current public material; clinical, provider, pharmacy, and medication availability should be confirmed during intake.
Treatment & pricing data
Published programs
Prices are stored separately from memberships and other program fees. Promotional rates remain labeled as promotional rather than being presented as the standard price.
| Program | Treatment | Form | Published price | What the price includes | Pricing last checked |
|---|---|---|---|---|---|
| Oral SemaglutideCompounded | semaglutide | pill · oral | $149 / monthPromotional · first monthFirst-month advertised starting price only; continuing cost and dose terms not publicly specified. Compounded medication is not FDA-approved.Price verified: Nov 9, 2026 | See program details | Nov 9, 2026 |
| Semaglutide InjectionCompounded | semaglutide | injection · subcutaneous | $99 / monthPromotional · first monthFirst-month advertised starting price only; continuing cost and dose terms not publicly specified. Compounded medication is not FDA-approved.Price verified: Nov 9, 2026 | See program details | Nov 9, 2026 |
| Sermorelin InjectionCompounded | sermorelin | injection · subcutaneous | $199 / monthStandard · standard monthlyAdvertised monthly price for compounded sermorelin; no membership fee. A clinician must determine eligibility.Price verified: Nov 9, 2026 | See program details | Nov 9, 2026 |
| Tirzepatide InjectionCompounded | tirzepatide | injection · subcutaneous | $99 / monthPromotional · first monthFirst-month advertised starting price only; continuing cost and dose terms not publicly specified. Compounded medication is not FDA-approved.Price verified: Nov 9, 2026 | See program details | Nov 9, 2026 |
Regulatory history
Dated public actions
This section records sourced regulatory events as dated facts. An event is not converted into a provider score or ranking adjustment.
FDA stated that SkinnyRx website claims concerning compounded semaglutide and tirzepatide were false or misleading, including claims implying FDA approval or sameness with FDA-approved medications. The event is recorded as a dated regulatory action, not an editorial rating.
RightFit is an independent publisher. Visit the provider for eligibility, prescribing, and current checkout terms.
Visit SkinnyRx ↗